drugset / Trial / NCT02258867

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

NCT02258867

Phase 3 Terminated 4 enrolled XOMA (US) LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to assess the efficacy and safety of gevokizumab in treating Behcet's disease uveitis (BDU).

Timeline

Start
2014-11
Primary completion
2015-10
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject gevokizumab Monoclonal antibody Subcutaneous

Indications